Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...